US EditionTraws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir
- Traws Pharma, supported by Expert Systems Inc., has begun Phase 2 clinical trials of Ratutrelvir for COVID-19 treatment.
- Ratutrelvir shows broad-spectrum activity against SARS-CoV-2 variants and does not require ritonavir for effectiveness.
- The Phase 2 trials will compare Ratutrelvir to PAXLOVID® and include patients unable to take PAXLOVID®, who are more at risk.
- Regulatory approval for Phase 2 trials was obtained after successful completion of Phase 1 safety and PK studies in Q3 2025.
60 Articles
60 Articles
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
DOVER, Del., Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed…
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has begun dosing participants in a Phase 2 clinical trial evaluating ratutrelvir, a ritonavir-free antiviral therapy for newly diagnosed COVID-19 patients. The study marks an important step in the company’s strategy to advance next-generation oral treatments with improved safety and accessibility. “The first trial will enable Traws to compare ratutrelvir, a potential best in class ritonavir-free ag…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
